A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle
Study Details
Study Description
Brief Summary
A Single-Center study to demonstrate the non-inferiority of EM-100 to Zaditor® in the treatment of ocular itching.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: EM-100 One drop of EM-100 in either the right or left eye once on Day 1. |
Drug: EM-100
Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
|
Experimental: Zaditor® One drop of Zaditor® in either the right or left eye once on Day 1. |
Drug: Zaditor®
Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
|
Experimental: Vehicle One drop of Vehicle in either the right or left eye once on Day 1. |
Drug: Vehicle
Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
|
Outcome Measures
Primary Outcome Measures
- Ocular Itching [3, 5 and 7 minutes post-Conjunctival Allergen Challenge (CAC) on Day 1]
Ocular itching scores were self-assessed by the participant using a 5-point scale with 0.5 unit increments, wherein 0 = None (normal, no itching), 1.0 = Intermittent tickle sensation involving more than just the corner of the eye, 2.0 = Mild continuous itch without desire to rub, 3.0 = Severe itch with desire to rub, and 4.0 = Incapacitating itch with irresistible urge to rub.
Secondary Outcome Measures
- Conjunctival Redness [7, 15 and 20 minutes post-Conjunctival Allergen Challenge (CAC) on Day 1]
The investigator assessed conjunctival redness scores using a 5-point scale with 0.5 unit increments, wherein 0 = None (normal, no dilated blood vessels), 1 = Mild (slightly dilated blood vessels: pink color; can be quadrantal), 2 = Moderate (more apparent dilation, with redder color, involving majority of the vessel bed), 3 = Severe (numerous and obvious dilated blood vessels, with deep red color and no color, or less red with chemosis), and 4 = Extremely Severe (large, numerous, dilated blood vessels characterized by unusually severe deep red color regardless of chemosis and involving the entire vessel bed).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
be at least 18 years old
-
have a positive history of allergic conjunctivitis and positive skin test reaction to allergens
-
be willing to avoid disallowed medications for the appropriate washout period and throughout the trial
-
be willing to avoid contact lens use
-
be willing to have a pregnancy test
-
must be able to read an eye chart from 10 feet away
Exclusion Criteria:
-
must not have any allergies to the study medications
-
must not have any ocular or non ocular condition that investigator feels will interfere with study parameters
-
must not have used an investigational drug or device in the past 30 days or currently be enrolled in another investigational trial
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Total Eye Care, PA | Memphis | Tennessee | United States | 38119 |
Sponsors and Collaborators
- Bausch & Lomb Incorporated
- ORA, Inc.
Investigators
None specified.Study Documents (Full-Text)
More Information
Publications
None provided.- 17-100-0011
Study Results
Participant Flow
Recruitment Details | There were 65 participants enrolled (130 eyes). 38 participants received EM-100 in one eye and Zaditor in the other eye. 13 participants received EM-100 in one eye and vehicle in the other eye. 14 participants received Zaditor in one eye and vehicle in the other eye. Thus, of 65 participants, 51 received EM-100 in one of their eyes, 52 received Zaditor in one of their eyes, and 27 received vehicle in one of their eyes. Each participant received 2 of the 3 study treatments, one in each eye. |
---|---|
Pre-assignment Detail |
Arm/Group Title | EM-100 | Zaditor® | Vehicle |
---|---|---|---|
Arm/Group Description | One drop of EM-100 in either the right or left eye once on Day 1. EM-100: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial. | One drop of Zaditor® in either the right or left eye once on Day 1. Zaditor®: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial. | One drop of Vehicle in either the right or left eye once on Day 1. Vehicle: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial. |
Period Title: Overall Study | |||
STARTED | 51 | 52 | 27 |
COMPLETED | 51 | 52 | 27 |
NOT COMPLETED | 0 | 0 | 0 |
Baseline Characteristics
Arm/Group Title | Overall Participants |
---|---|
Arm/Group Description | The 65 enrolled participants had one of the three study treatments instilled in each eye (each subject had 2 of the 3 different treatments, one in each eye). Demographic data were not collected by treatment or by eye. |
Overall Participants | 65 |
Age (years) [Mean (Standard Deviation) ] | |
Mean (Standard Deviation) [years] |
44.4
(12.16)
|
Sex: Female, Male (Count of Participants) | |
Female |
44
67.7%
|
Male |
21
32.3%
|
Race (NIH/OMB) (Count of Participants) | |
American Indian or Alaska Native |
0
0%
|
Asian |
0
0%
|
Native Hawaiian or Other Pacific Islander |
0
0%
|
Black or African American |
36
55.4%
|
White |
29
44.6%
|
More than one race |
0
0%
|
Unknown or Not Reported |
0
0%
|
Iris color (Count of Participants) | |
Black |
1
1.5%
|
Blue |
8
12.3%
|
Brown |
46
70.8%
|
Hazel |
6
9.2%
|
Green |
4
6.2%
|
Outcome Measures
Title | Ocular Itching |
---|---|
Description | Ocular itching scores were self-assessed by the participant using a 5-point scale with 0.5 unit increments, wherein 0 = None (normal, no itching), 1.0 = Intermittent tickle sensation involving more than just the corner of the eye, 2.0 = Mild continuous itch without desire to rub, 3.0 = Severe itch with desire to rub, and 4.0 = Incapacitating itch with irresistible urge to rub. |
Time Frame | 3, 5 and 7 minutes post-Conjunctival Allergen Challenge (CAC) on Day 1 |
Outcome Measure Data
Analysis Population Description |
---|
The 65 enrolled participants had one of the three study treatments instilled in each eye (each subject had 2 different treatments, one in each eye). |
Arm/Group Title | EM-100 | Zaditor® | Vehicle |
---|---|---|---|
Arm/Group Description | One drop of EM-100 in either the right or left eye once on Day 1. EM-100: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial. | One drop of Zaditor® in either the right or left eye once on Day 1. Zaditor®: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial. | One drop of Vehicle in either the right or left eye once on Day 1. Vehicle: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial. |
Measure Participants | 51 | 52 | 27 |
Measure eyes | 51 | 52 | 27 |
3 minutes post CAC |
0.81
(0.787)
|
0.79
(0.750)
|
1.98
(0.935)
|
5 minutes post CAC |
1.09
(1.047)
|
1.04
(0.989)
|
2.17
(1.00)
|
7 minutes post CAC |
1.17
(1.103)
|
1.04
(1.047)
|
2.22
(1.032)
|
Title | Conjunctival Redness |
---|---|
Description | The investigator assessed conjunctival redness scores using a 5-point scale with 0.5 unit increments, wherein 0 = None (normal, no dilated blood vessels), 1 = Mild (slightly dilated blood vessels: pink color; can be quadrantal), 2 = Moderate (more apparent dilation, with redder color, involving majority of the vessel bed), 3 = Severe (numerous and obvious dilated blood vessels, with deep red color and no color, or less red with chemosis), and 4 = Extremely Severe (large, numerous, dilated blood vessels characterized by unusually severe deep red color regardless of chemosis and involving the entire vessel bed). |
Time Frame | 7, 15 and 20 minutes post-Conjunctival Allergen Challenge (CAC) on Day 1 |
Outcome Measure Data
Analysis Population Description |
---|
The 65 enrolled participants had one of the three study treatments instilled in each eye (each subject had 2 different treatments, one in each eye). |
Arm/Group Title | EM-100 | Zaditor® | Vehicle |
---|---|---|---|
Arm/Group Description | One drop of EM-100 in either the right or left eye once on Day 1. EM-100: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial. | One drop of Zaditor® in either the right or left eye once on Day 1. Zaditor®: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial. | One drop of Vehicle in either the right or left eye once on Day 1. Vehicle: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial. |
Measure Participants | 51 | 52 | 27 |
7 minutes post-CAC |
2.13
(0.824)
|
2.14
(0.743)
|
2.72
(0.725)
|
15 minutes post-CAC |
2.25
(0.783)
|
2.29
(0.737)
|
2.61
(0.847)
|
20 minutes post-CAC |
2.16
(0.857)
|
2.24
(0.704)
|
2.46
(0.784)
|
Adverse Events
Time Frame | 1 day | |
---|---|---|
Adverse Event Reporting Description | ||
Arm/Group Title | Overall Participants | |
Arm/Group Description | The 65 enrolled participants had one of the three study treatments instilled in each eye (each subject had 2 of the 3 different treatments, one in each eye). | |
All Cause Mortality |
||
Overall Participants | ||
Affected / at Risk (%) | # Events | |
Total | 0/65 (0%) | |
Serious Adverse Events |
||
Overall Participants | ||
Affected / at Risk (%) | # Events | |
Total | 0/65 (0%) | |
Other (Not Including Serious) Adverse Events |
||
Overall Participants | ||
Affected / at Risk (%) | # Events | |
Total | 0/65 (0%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
Please contact sponsor directly for details.
Results Point of Contact
Name/Title | Heleen DeCory |
---|---|
Organization | Bausch & Lomb |
Phone | (585) 338-8161 |
heleen.decory@bausch.com |
- 17-100-0011